U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Platinum-Resistant Fallopian Tube Carcinoma

MedGen UID:
1677574
•Concept ID:
C4763749
•
Neoplastic Process
Synonym: Platinum-Resistant Fallopian Tube Cancer

Definition

Fallopian tube carcinoma that progresses between one and six months of completing the last platinum therapy. [from NCI]

Professional guidelines

PubMed

Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A, Mahner S, Moore KN, Lorusso D, Coleman RL
Int J Gynecol Cancer 2023 Mar 6;33(3):420-429. doi: 10.1136/ijgc-2022-003701. PMID: 36878560
New strategies in ovarian cancer treatment.
Lee JM, Minasian L, Kohn EC
Cancer 2019 Dec 15;125 Suppl 24(Suppl 24):4623-4629. doi: 10.1002/cncr.32544. PMID: 31967682Free PMC Article
Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
Webber K, Friedlander M
Best Pract Res Clin Obstet Gynaecol 2017 May;41:126-138. Epub 2016 Nov 23 doi: 10.1016/j.bpobgyn.2016.11.004. PMID: 28027849

Recent clinical studies

Etiology

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ
Int J Gynecol Cancer 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. PMID: 38101816
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, Ricks TK, Pragani R, Arudchandran A, Patel P, Zaman S, Roy A, Kalavar S, Ghosh S, Pierce WF, Rahman NA, Tang S, Mixter BD, Kluetz PG, Pazdur R, Amiri-Kordestani L
Clin Cancer Res 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. PMID: 37212825Free PMC Article
New Drug Treats Female Reproductive Cancers.
Aschenbrenner DS
Am J Nurs 2023 Apr 1;123(4):25. doi: 10.1097/01.NAJ.0000925492.07716.f4. PMID: 36951341
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ
Lancet Oncol 2021 Jul;22(7):1034-1046. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00216-3. PMID: 34143970
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K
JAMA Oncol 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. PMID: 33211063Free PMC Article

Diagnosis

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ
Int J Gynecol Cancer 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. PMID: 38101816
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, Ricks TK, Pragani R, Arudchandran A, Patel P, Zaman S, Roy A, Kalavar S, Ghosh S, Pierce WF, Rahman NA, Tang S, Mixter BD, Kluetz PG, Pazdur R, Amiri-Kordestani L
Clin Cancer Res 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. PMID: 37212825Free PMC Article
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ
Lancet Oncol 2021 Jul;22(7):1034-1046. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00216-3. PMID: 34143970
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K
JAMA Oncol 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. PMID: 33211063Free PMC Article
The Many Microenvironments of Ovarian Cancer.
Micek HM, Visetsouk MR, Fleszar AJ, Kreeger PK
Adv Exp Med Biol 2020;1296:199-213. doi: 10.1007/978-3-030-59038-3_12. PMID: 34185294Free PMC Article

Therapy

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, Ricks TK, Pragani R, Arudchandran A, Patel P, Zaman S, Roy A, Kalavar S, Ghosh S, Pierce WF, Rahman NA, Tang S, Mixter BD, Kluetz PG, Pazdur R, Amiri-Kordestani L
Clin Cancer Res 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. PMID: 37212825Free PMC Article
New Drug Treats Female Reproductive Cancers.
Aschenbrenner DS
Am J Nurs 2023 Apr 1;123(4):25. doi: 10.1097/01.NAJ.0000925492.07716.f4. PMID: 36951341
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, Provencher D, Memarzadeh S, Method M, Wang J, Moore KN, O'Malley DM
Gynecol Oncol 2023 Mar;170:241-247. Epub 2023 Feb 1 doi: 10.1016/j.ygyno.2023.01.020. PMID: 36736157
Mirvetuximab Soravtansine: First Approval.
Heo YA
Drugs 2023 Feb;83(3):265-273. doi: 10.1007/s40265-023-01834-3. PMID: 36656533
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K
JAMA Oncol 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. PMID: 33211063Free PMC Article

Prognosis

Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.
Nwabufo CK
Cancer Chemother Pharmacol 2024 Feb;93(2):89-105. Epub 2023 Aug 18 doi: 10.1007/s00280-023-04575-y. PMID: 37594572
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee S, Giannone G, Clamp AR, Ennis DP, Glasspool RM, Herbertson R, Krell J, Riisnaes R, Mirza HB, Cheng Z, McDermott J, Green C, Kristeleit RS, George A, Gourley C, Lewsley LA, Rai D, Banerji U, Hinsley S, McNeish IA
JAMA Oncol 2023 May 1;9(5):675-682. doi: 10.1001/jamaoncol.2022.7966. PMID: 36928279Free PMC Article
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
Tatsuki S, Shoji T, Abe M, Tomabechi H, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Aida T, Baba T
Anticancer Res 2022 Sep;42(9):4603-4610. doi: 10.21873/anticanres.15964. PMID: 36039449
The Many Microenvironments of Ovarian Cancer.
Micek HM, Visetsouk MR, Fleszar AJ, Kreeger PK
Adv Exp Med Biol 2020;1296:199-213. doi: 10.1007/978-3-030-59038-3_12. PMID: 34185294Free PMC Article
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?
Markman M, Hakes T, Reichman B, Barakat R, Curtin J, Jones W, Lewis JL Jr, Rubin S, Almadrones L, Hoskins W
Semin Oncol 1992 Dec;19(6 Suppl 14):25-7. PMID: 1488652

Clinical prediction guides

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, Provencher D, Memarzadeh S, Method M, Wang J, Moore KN, O'Malley DM
Gynecol Oncol 2023 Mar;170:241-247. Epub 2023 Feb 1 doi: 10.1016/j.ygyno.2023.01.020. PMID: 36736157
Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T, Enomoto T, Abe M, Okamoto A, Nagasawa T, Oishi T, Nagase S, Mori M, Inokuchi Y, Kamiura S, Komiyama S, Takeshima N, Sugiyama T
Cancer Sci 2022 Jan;113(1):240-250. Epub 2021 Nov 18 doi: 10.1111/cas.15185. PMID: 34716979Free PMC Article
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN
Gynecol Oncol 2020 May;157(2):379-385. Epub 2020 Feb 18 doi: 10.1016/j.ygyno.2020.01.037. PMID: 32081463
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ
J Clin Oncol 2017 Apr 1;35(10):1112-1118. Epub 2016 Dec 28 doi: 10.1200/JCO.2016.69.9538. PMID: 28029313Free PMC Article
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?
Markman M, Hakes T, Reichman B, Barakat R, Curtin J, Jones W, Lewis JL Jr, Rubin S, Almadrones L, Hoskins W
Semin Oncol 1992 Dec;19(6 Suppl 14):25-7. PMID: 1488652

Recent systematic reviews

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Newhouse R, Nelissen E, El-Shakankery KH, Rogozińska E, Bain E, Veiga S, Morrison J
Cochrane Database Syst Rev 2023 Jul 5;7(7):CD006910. doi: 10.1002/14651858.CD006910.pub3. PMID: 37407274Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...